Other News To Note

August 2013
BioWorld International;8/7/2013, Vol. 18 Issue 32, p5
This section offers news briefs on the pharmaceutical industry as of August 2013. Apeiron Biologics AG and Rentschler Biotechnologie GmbH partnered in the production of GMP material for the neuroblastoma chimeric antibody APN311. Oramed Pharmaceuticals Inc. presented a pre-examination meeting request for a trial testing of ORMD-0901 in the U.S. Redhill Biopharma Ltd. of Tel Aviv, Israel reveals positive results of RHB-104 preclinical study for rheumatoid arthritis treatment.


Related Articles

  • Rentschler, Boehringer Team Up to Offer Biopharma Services. Ramesh, Deepti // Chemical Week;6/2/2008, Vol. 170 Issue 17, p27 

    The article reports on the preferred partnership signed by biopharmaceutical contract manufacturer Rentschler Biotechnologie with leading pharmaceutical company Boehringer Ingelheim. The agreement provides Rentschler Biotechnologie's customers with access to Boehringer Ingelheim's large-scale...

  • Expansions.  // Pharmaceutical Technology;Sep2006, Vol. 30 Issue 9, p130 

    The article reports growth and expansions in the pharmaceutical industry. Biopharmaceutical contract manufacturer Rentschler Biotechnologie company will invest 50 million Euro for the expansion of its facilities at Laupheim. HollisterStier Laboratories company has bought a seven-acre lot for the...

  • News and Views.  // Pharmaceutical Technology;Dec2005, Vol. 29 Issue 12, p80 

    The article presents information on the latest developments in the pharmaceutical industry. Connecticut-based ABB Inc. has announced that its ABB Inc. Automation World Users conference and exhibition will be held on May 9-12, 2006 in Houston, Texas. North Carolina-based AAIPharma Inc. has made a...

  • Equipped for Success. Mayberry, Jonnatha // Pharmaceutical Processing;Apr2012, Vol. 27 Issue 3, p26 

    The article announces that Rentschler Biotechnologie GmbH has received the 2012 Facility of the Year Award (FOYA) for Equipment Innovation.

  • Pipeline.  // Medical Marketing & Media;Dec2012, Vol. 47 Issue 12, p16 

    The article offers world news briefs related to the pharmaceutical industry including the approval of Xarelto to treat deep vein thrombosis by the U.S. Food and Drug Administration (FDA), and the release of Phase III on the oral rheumatoid arthritis drug fostamatinib of AstraZeneca.

  • South Korea Gives OK To Biosimilar.  // Chain Drug Review;9/28/2015, Vol. 37 Issue 15, p129 

    The article reports on the approval by South Korean regulators on the sale of the biosimilars Brenzys, from Merck and Samsung Bioepis Co., for the treatment of rheumatoid arthritis and other conditions in adults in the country.

  • WEEK IN REVIEW.  // BioWorld Insight;6/27/2011, Vol. 19 Issue 26, p5 

    The article offers news briefs related to pharmaceutical industry. Ultragenyx Pharmaceutical Inc. has raised 45 million dollars in Series A funding for orphan disease. Apeiron Biologics AG has obtained a licensed rights to a Phase III anti-GD2 antibody for neuroblastoma from academia. The Eylea...

  • WEEK IN REVIEW.  // BioWorld Insight;2/8/2010, Vol. 18 Issue 6, p5 

    The article offers news briefs related to the biopharmaceutical industry. BG Medicine Inc. has planned to secure 86.25 million dollars through an initial public offering. Apeiron Biologics AG has signed an agreement with GlaxoSmithKline for a preclinical alternative to angiotensin-converting...

  • NEWSLINE.  // MPR - Pharmacist's Edition;Winter2012/2013, Vol. 6 Issue 4, pA-8 

    The article focuses on news briefs related to the drug approvals. Approval for the treatment of moderately-to-severely active rheumatoid arthritis (RA) has been given to the drug Xeljanz tablets in patients who have had an inadequate response or intolerance to methotrexate. Clinical remission is...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics